US Food and Drug Administration Accepts New Drug Application for Ensartinib – ILCN.org (ILCN/WCLC)
The filing was based on results from a global phase III study designed to compare the ALK inhibitor to crizotinib in the first-line treatment of ALK-positive NSCLC.